Cancer and Leukemia Group B-Leukemia Correlative Science

癌症与白血病B组-白血病相关科学

• 批准号: 6747915
• 负责人: MICHAEL A CALIGIURI
• 金额: $ 103.92万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-13 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6747915
• 关键词: blood /lymphatic neoplasm; clinical research; cooperative study; cytogenetics; leukemia; molecular oncology

The Cancer and Leukemia Group B (CALGB) Leukemia Correlative Sciences Program has worked to attain a highly successful integration of correlative laboratory studies into the design and implementation of CALGB leukemia trials. Dr. Michael A. Caligiuri assumed leadership of the CALGB Leukemia Correlative Science Committee (LCSC) in August of 1999 following 18 years of Committee leadership by Dr. Clara Bloomfield. The LCSC has been restructured and refocused entirely on leukemia, moving evermore into the molecular age of diagnostics, pathogenesis, and treatment. The goal is to use cytogenetics, immunology, and molecular biology to better understand the heterogeneity of leukemia with regard to diagnosis, prognosis, and ultimately treatment. In this competitive renewal application, we have assembled three Cores (Cytogenetics, Banking, and Administration) and six Projects, each of which is utilizing materials collected from patients treated on CALGB leukemia treatment protocols in order to address a scientific question and correlate it with disease outcome. Having set into motion a paradigm for stratification of leukemia treatment based on risk of relapse during this last funding cycle, the current CALGB Leukemia Correlative Science application will attempt to dissect out additional leukemia patients that can be predicted to do well or do poorly in response to standard or novel therapies, and to then work with the CALGB Leukemia disease committee to stratify their treatment based on risk. In this way, we hope to significantly impact on the cure rate of leukemia over the next six years of funding.

癌症和白血病B组（CALB）白血病相关科学计划已致力于将相关实验室研究非常成功地整合到CALGB白血病试验的设计和实施中。 Michael A. Caligiuri博士在Clara Bloomfield博士担任了18年的委员会领导之后，于1999年8月担任Calgb白血病相关科学委员会（LCSC）的领导。 LCSC已被重组和重新集中在白血病上，并将其移至诊断，发病机理和治疗的分子年龄。目的是使用细胞遗传学，免疫学和分子生物学来更好地了解白血病在诊断，预后和最终治疗方面的异质性。 在此竞争性更新应用中，我们组装了三个核心（细胞遗传学，银行业和行政管理）和六个项目，每个项目都利用从在CALB白血病治疗方案中收集的材料收集的材料，以解决科学问题并将其与疾病结果相关联。设置运动范式以基于在最后一次融资周期中复发的风险分层的白血病治疗范式，当前的CALGB白血病相关科学应用将试图剖析 可以预测的其他白血病患者可以响应标准或新型疗法，并与CALGB白血病委员会合作，根据风险将其治疗分层。这样，我们希望在接下来的六年资金中对白血病的治愈率产生重大影响。